Home›Trial›NCT05024045
🔬NCT05024045Phase 1ACTIVE NOT RECRUITING

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Study Summary

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

Conditions
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-cell Marginal ZoneLymphoma, Non-HodgkinMultiple MyelomaB-cell LymphomaWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell
Interventions / Drugs
LOXO-338Pirtobrutinib
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment316 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865889+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.